Advanced Search
Therapeutic Area Disease
Title Drug Phase
Clinical Trials Listing
Active treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
UPCC 1412 INSPIRE for Survivorship After Transplant: A Multicenter Randomized Controlled Trial of an Internet and Social-media Program for Long-term Hematopoietic Cell Transplantation Survivors III Supportive Care Not Applicable
AT005074 Long-Term Chamomile Therapy for Generalized Anxiety Disorder (GAD) III Supportive Care Not Applicable
UPCC-34412 Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma III Immunotherapy (Monoclonal Antibody), Signal Transduction Inhibitor vorinostat; KW-0761 (mogamulizumab)
715 A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) Versus HLA-Haploidentical Related Bone Marrow (Haplo-BM) for Patients With Hematologic Malignancies (BMT CTN #1101) III Immunotherapy Not Applicable
NCI-2014-00118 A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL) III Chemotherapy, Immunotherapy (Monoclonal Antibody), Signal Transduction Inhibitor fludarabine; rituximab; cyclophosphamide; ibrutinib
UPCC-05912 Extended Duration Varenicline for Smoking Among Cancer Patients: A Clinical Trial III Other, Supportive Care varenicline tartrate
#1R01FD003410-01 A Phase 3 Trial of Calfactant for ALI in Pediatric Leukemia and HSCT Patients II / III Other calfactant
13D.127 A Two Step Approach to Haploidentical Hematopoietic Stem Cell Transplantation for Patients in Remission From HLA Partially-Matched Related Donors-Effect of Maternal Donors on Outcomes II Bone Marrow Transplant / Stem Cell Transplant, Radiation Therapy Not Applicable
13D.352 A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor II Bone Marrow Transplant / Stem Cell Transplant, Chemotherapy, Radiation Therapy cyclophosphamide; mycophenolate mofetil
08D.85 A Two Step Approach To Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematological Malignancies II Bone Marrow Transplant / Stem Cell Transplant Not Applicable
12D.501 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies II Bone Marrow Transplant / Stem Cell Transplant, Radiation Therapy Not Applicable
13-010495 UNRELATED AND PARTIALLY MATCHED RELATED DONOR PERIPHERAL STEM CELL TRANSPLANTATION WITH Alpha/Beta T CELL AND B CELL DEPLETION FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES II Chemotherapy busulfan; thiotepa; cyclophosphamide
11D.51 Post Transplant Cyclophosphamide for Unrelated and Related Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies II Bone Marrow Transplant / Stem Cell Transplant, Chemotherapy, Radiation Therapy, Immunotherapy fludarabine; thiotepa; cyclophosphamide; mycophenolate mofetil; tacrolimus
11D.247 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies II Chemotherapy, Radiation Therapy, Immunotherapy fludarabine; thiotepa; cyclophosphamide; mycophenolate mofetil; tacrolimus
NCI-2014-00709 A Phase 2 Study of MK-3475 for the Treatment of Relapsed/Refractory Mycosis Fungoides/Sézary Syndrome II Immunotherapy (Monoclonal Antibody) pembrolizumab
CD-ON-MEDI-551-1088 A Phase 2 Randomized Open-label Study of an Investigational Drug in Adults With Relapsed or Refractory DLBCL II Chemotherapy, Hormonal Therapy, Immunotherapy (Monoclonal Antibody) carboplatin; cisplatin; etoposide; ifosfamide; rituximab; cytarabine; dexamethasone;
BMTCTN1203 A Multi-center Phase II Trial Randomizing Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN #1203) II Chemotherapy, Signal Transduction Inhibitor bortezomib; methotrexate; tacrolimus
UPCC-04712 A Phase II Study to Assess the Efficacy of Maraviroc, a CCR5-Antagonist in Prophylaxis of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Undergoing Reduced-Intensity Allogeneic Stem-Cell Transplantation From Unrelated Donors II Supportive Care Maraviroc
UPCC 13413 Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas II Immunotherapy CART 19
UPCC-03712 Dose Optimization Trial of Autologous T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (CART-19) in Patients with Relapsed or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL) II Immunotherapy CART 19
710 Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals II Chemotherapy, Radiation Therapy fludarabine; busulfan; melphalan; cyclophosphamide
PSHCI 10-011 Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma: A Phase I/II Study (PSHCI 10-011) I / II Chemotherapy, Immunotherapy (Monoclonal Antibody), Signal Transduction Inhibitor bortezomib; cladribine; rituximab
11D.404 Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-cell Lymphomas I / II Chemotherapy, Immunotherapy (Monoclonal Antibody) carboplatin; etoposide; bendamustine hydrochloride ; ofatumumab
D2852C00004 A Phase 1b/2 Open-label Study to Evaluate the Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapy in Subjects With Relapsed or Refractory Aggressive B-cell Lymphomas I / II Immunotherapy
UPCC-17413 A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas I / II Immunotherapy (Monoclonal Antibody), Immunotherapy brentuximab vedotin
UPCC-11411 Maintenance Lenalidomide in Lymphoma I / II Immunomodulatory Agent lenalidomide
110060 A Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction I Signal Transduction Inhibitor belinostat
CA209-039 A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS-936558) in Subjects With Relapsed or Refractory Hematologic Malignancy I Immunotherapy (Monoclonal Antibody) nivolumab
MI-CP204 A Phase 1, Dose-escalation Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies I Immunotherapy (Monoclonal Antibody)
CHP959 Pilot Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma I Immunotherapy CART 19
11D.166 Phase I Trial With Cohort Expansion of Pentostatin, Bendamustine and Ofatumumab (PBO) for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma I Chemotherapy, Immunotherapy (Monoclonal Antibody) pentostatin; bendamustine hydrochloride ; ofatumumab
13-131 Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source I Chemotherapy, Signal Transduction Inhibitor mesna; fludarabine; cyclophosphamide; tacrolimus; G-CSF; mycophenolate sodium (mycophenolic acid)
UPCC-35414 A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies I Immunotherapy (Monoclonal Antibody) rituximab;
UPCC-03714 A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies I Signal Transduction Inhibitor
UPCC 27914 A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer I Biological Therapy, Chemotherapy, Hormonal Therapy letrozole; midazolam;
UPCC 25414 A Phase Ib, Open-Label Study Evaluating The Safety And Pharmacokinetics Of GDC-0199 (ABT-199) In Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine And Prednisone (Chope) In Patients With B-Cell Non-Hodgkins Lymphoma (NHL) and DLBCL I Biological Therapy, Chemotherapy, Hormonal Therapy, Immunotherapy (Monoclonal Antibody) vincristine; rituximab; prednisone; cyclophosphamide; doxorubicin; obinutuzumab; GDC-0199 (ABT-199 / RG7601)
UPCC-44414 A Phase I/II Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies I Signal Transduction Inhibitor
UPCC 12414 A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Subjects With Relapsed/Refractory Multiple Myeloma and Other Advanced Hematologic Malignancies Expressing BCMA I Immunotherapy
UPCC 30914 Choosing Options for Insomnia in Cancer Effectively (CHOICE): A Comparative Effectiveness Trial of Acupuncture and Cognitive Behavior Therapy 0 Complementary and Alternative Therapy Not Applicable
UPCC 12914 A Pilot Study Using FDG-PET/CT Imaging as an Early Predictor of Disease Response in Lymphoma Subjects Receiving Redirected Autologous CART- 19 T-cell Immunotherapy 0 Immunotherapy CART 19
STUDY00000378 The Value of Integrating Visual Arts (VIVA): Evaluating the Benefits of Hospital Room Artwork on Inpatient Wellbeing Not Specified Not Applicable
14D.272 Use of a Brief Mindful Meditation Practice in Adult Cancer Patients Receiving Radiation Therapy Not Specified Not Applicable
UPCC-12807 Assessing Fertility Potential in Female Cancer Survivors Not Specified Imaging Procedure, Blood or Tissue Collection Not Applicable
NCT01295658 Cancer Experience Registry Not Specified Not Applicable
Active non-treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug

Sorry, your search did not return any Penn Non-Treatment Trials trials

Active advanced solid tumor trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug

Sorry, your search did not return any Phase 1: Solid Tumor Trials trials

Active proton therapy trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug

Sorry, your search did not return any Proton Therapy Trials trials

Request a call

A clinical trial navigator is available to help you search for clinical trials offered by the Penn Medicine Abramson Cancer Center. This is a confidential free service available Monday-Friday, 9:00am-5:00pm (ET). Requests are processed in the order they are received.



*
*
*
*

Please do not submit another person’s name or email without his or her consent.